New inhibitors of 17β-hydroxysteroid dehydrogenase type 1

The estradiol-synthesizing enzyme 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) is mainly responsible for the conversion of estrone (E1) to the potent estrogen estradiol (E2). It is a key player to control tissue levels of E2 and is therefore an attractive target in estradiol-dependent diseases...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and cellular endocrinology 2006-03, Vol.248 (1), p.192-198
Main Authors: Messinger, Josef, Hirvelä, Leena, Husen, Bettina, Kangas, Lauri, Koskimies, Pasi, Pentikäinen, Olli, Saarenketo, Pauli, Thole, Hubert
Format: Article
Language:English
Subjects:
17β-Hydroxysteroid dehydrogenase type 1
17βHSD1
Inhibitor
Pyrimidinone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The estradiol-synthesizing enzyme 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) is mainly responsible for the conversion of estrone (E1) to the potent estrogen estradiol (E2). It is a key player to control tissue levels of E2 and is therefore an attractive target in estradiol-dependent diseases like breast cancer or endometriosis. We selected a unique non-steroidal pyrimidinone core to start a lead optimization program. We optimized this core by modulation of R1–R6. Its binding mode at the substrate-binding site of 17βHSD1 is complex and difficult to predict. Nevertheless, some basic structure–activity relationships could be identified. In vitro, the most active pyrimidinone derivative showed effective inhibition of recombinant human 17βHSD1 at nanomolar concentrations. In intact cells overexpressing the human enzyme, IC50 values in the lower micromolar range were determined. Furthermore, the pyrimidinone proved its use in vivo by significantly reducing 17βHSD1-dependent tumor growth in a new nude mouse model.
ISSN:0303-7207
1872-8057
DOI:10.1016/j.mce.2005.11.044